Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic...
Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.